Wnt proteins modulate cell proliferation and differentiation and the self-renewal of stem cells by inducing β-catenin-dependent signalling through the Wnt receptor frizzled (FZD) and the coreceptors LRP5 and LRP6 to regulate cell fate decisions and the growth and repair of several tissues 1 . The 19 mammalian Wnt proteins are cross-reactive with the 10 FZD receptors, and this has complicated the attribution of distinct biological functions to specific FZD and Wnt subtype interactions. Furthermore, Wnt proteins are modified post-translationally by palmitoylation, which is essential for their secretion, function and interaction with FZD receptors 2-4 . As a result of their acylation, Wnt proteins are very hydrophobic and require detergents for purification, which presents major obstacles to the preparation and application of recombinant Wnt proteins. This hydrophobicity has hindered the determination of the molecular mechanisms of Wnt signalling activation and the functional importance of FZD subtypes, and the use of Wnt proteins as therapeutic agents. Here we develop surrogate Wnt agonists, water-soluble FZD-LRP5/LRP6 heterodimerizers, with FZD5/FZD8-specific and broadly FZDreactive binding domains. Similar to WNT3A, these Wnt agonists elicit a characteristic β-catenin signalling response in a FZDselective fashion, enhance the osteogenic lineage commitment of primary mouse and human mesenchymal stem cells, and support the growth of a broad range of primary human organoid cultures. In addition, the surrogates can be systemically expressed and exhibit Wnt activity in vivo in the mouse liver, regulating metabolic liver zonation and promoting hepatocyte proliferation, resulting in hepatomegaly. These surrogates demonstrate that canonical Wnt signalling can be activated by bi-specific ligands that induce receptor heterodimerization. Furthermore, these easily produced, non-lipidated Wnt surrogate agonists facilitate functional studies of Wnt signalling and the exploration of Wnt agonists for translational applications in regenerative medicine.
water-soluble Wnt agonists by linking antagonistic FZD and LRP5/ LRP6-binding modules into a single polypeptide chain, thus forcing receptor heterodimerization while blocking endogenous Wnt binding ( Fig. 1a ). We used FZD subtype-specific and cross-reactive binding modules for restricted and broad cell-type specificity, respectively. For the FZD subtype-specific binder, through an integration of de novo design and protein engineering using yeast surface display, we created B12, a four-helix bundle domain protein derived from Bacillus halodurans, which binds specifically to the closely related FZD proteins FZD5 and FZD8, with relative affinities of 9 and 18 nM ( Fig. 1a, b and Extended Data Figs 1, 2a-c). The crystal structure revealed that B12 binds FZD8 CRD at the rim of the lipid-binding groove engaging the FZD5/FZD8-specific Trp73 as hotspot residue. Leu56 and Leu61 in the loop following helix 2 bind to the groove, resulting in partial overlap with the Wnt lipid-binding site, and weak Wnt antagonism ( Fig. 1c and Extended Data Fig. 2d ). For the FZD cross-reactive analogue, we used the single-chain variable fragment (scFv) of the Wnt antagonizing antibody vantictumab, which binds FZD1, FZD2, FZD5, FZD7 and FZD8 with high affinity (0.7-1.4 nM) 9 (Fig. 1b and Extended Data Fig. 2e-h) . To create FZD-LRP5/LRP6 heterodimerizers, we linked the FZD-binding modules (B12 and scFv) to the C-terminal domain of the human Wnt antagonist DKK1. This C-terminal domain, which is sufficient for Wnt inhibition and binds LRP5/LRP6 with moderate affinity (20-70 nM) 10, 11 , was linked to B12 and scFv through a flexible Gly-Ser polypeptide linker of 0-15 amino acids and 5 amino acids, respectively (these fusions are referred to as B12-DKK1c and scFv-DKK1c throughout) ( Fig. 1a ).
To interrogate whether the surrogates heterodimerize and cluster FZD and LRP5/LRP6 on live cell surfaces comparably to Wnts 11, 12 , we probed the assembly and diffusion dynamics of FZD8 and LRP6 upon the addition of Wnt proteins and surrogates by dual-colour singlemolecule fluorescence imaging. FZD8 and LRP6 fused to an N-terminal SNAP-tag and HaloTag, respectively, were transiently expressed in HeLa cells and labelled with photostable fluorophores DY649 and tetramethylrhodamine (TMR), respectively 13 (Fig. 1d ). IWP-2, an inhibitor of endogenous Wnt secretion, reduced the basal low levels of receptor co-localization (Extended Data Fig. 3a and Supplementary Video 1). After the addition of scFv-DKK1c, B12-DKK1c, Xenopus Wnt8 (XWnt8) and WNT3A, FZD8-LRP6 complexes with reduced mobility were detected by co-locomotion and single complex trajectories analysis ( Fig. 1d , e, Extended Data Figs 3b, c, 4 and Supplementary Videos 2-5). In addition, the rates of FZD8-LRP6 dimerization and β -catenin accumulation induced by Wnt proteins and by surrogates correlate well (Extended Data Fig. 3d-j) . Moreover, complexes with increased intensities were observed, confirming comparable FZD8 and LRP6 oligomerization by Wnt proteins and surrogates (Extended Data Fig. 5 ).
To determine whether the surrogate proteins elicited FZD-specific activation of canonical Wnt signalling, we performed a series of reporter assays. scFv-DKK1c, but not B12-DKK1c, XWnt8 or negative controls, activated Wnt signalling in mouse L cells (expressing FZD7), which can be sensitized to B12-DKK1c and XWnt8 by specifically overexpressing FZD5 or FZD8 ( Fig. 2a-c and Extended Data Fig. 6a ). Although Wnt signalling in human A375 and SH-SY5Y cells (expressing FZD2) was robustly induced only by scFv-DKK1c, both surrogates induced reporter expression in A549 cells (expressing FZD2, FZD4, FZD6 and FZD8) (Extended Data Fig. 6b-d ). In agreement with their specificities, B12-DKK1c and scFv-DKK1c were antagonized by neutralizing (FZD8 CRD-Fc versus FZD1/FZD8 CRD-Fc) and blocking (isolated DKK1, B12 versus DKK1) domains (Extended Data Fig. 6e, f) . Furthermore, scFv-DKK1c triggered LRP6 phosphorylation and accumulation of β -catenin in A375 cells, comparable to WNT3A conditioned media, characteristic of canonical Wnt pathway activation (Extended Data Fig. 6g ). In addition, scFv-DKK1c and B12-DKK1c enhanced the transcription of the universal Wnt target gene AXIN2 in SH-SY5Y and A549 cells, respectively, similar to control Wnt proteins (Extended Data Fig. 6h , i). Notably, B12-DKK1c with different linkers displays differential activity as reflected in signalling amplitudes (Extended Data Fig. 6i, j) , demonstrating that the signal strength of the surrogate can be 'tuned' by variations in proximity of the binding modules. In HEK293 cells, RSPO2 strongly potentiates the activity of scFv-DKK1c, similar to WNT3A conditioned media 14 (Fig. 2d ), adding further validation to the surrogates signalling in a 'Wnt-like' mechanism. Furthermore, a single-chain fusion protein consisting of RSPO2 linked to the C-terminal end of scFv-DKK1c replicates the enhanced activity of the combination (Fig. 2d ).
Given that Wnt signalling has a pivotal role in bone formation 15 , we evaluated the activity of the Wnt surrogates on mesenchymal stem cells (MSCs). scFv-DKK1c and scFv-DKK1c-RSPO2 enhanced the dose-dependent upregulation of the early osteogenesis marker alkaline phosphatase (Alpl) in mouse C3H10T1/2 multipotent MSCs (mRNA and enzymatic activity) (Extended Data Fig. 7a, b ). In agreement with recent reports 16 , WNT3A and Wnt surrogates synergize with BMP2 to enhance upregulation of alkaline phosphatase, while suppressing expression of BMP2-induced chondrogenesis marker collagen 2A1 (Col2a1) ( Fig. 2e and Extended Data Fig. 7c, d) . A synergistic upregulation of alkaline phosphatase was also observed in primary human MSCs (mRNA and enzymatic activity) and mouse MSCs (enzymatic activity) ( Fig. 2f and Extended Data Fig. 7e-h ), suggesting that the Wnt surrogates could be therapeutic candidates to enhance bone regeneration.
In the presence of the required niche factors, such as WNT3A and RSPO, adult stem cells can develop into 3D organoids that resemble their corresponding organs, recapitulating their regenerative capacity ex vivo [17] [18] [19] [20] . To test whether scFv-DKK1c could substitute for WNT3A, we grew organoids from single-cell suspensions of normal human tissues in the presence or absence of recombinant scFv-DKK1c and scFv-DKK1c-RSPO2, and conditioned media from WNT3A, RSPO3 and IWP-2. Pancreas, stomach, colon and liver produce endogenous Wnt proteins, and organoids grow in the presence of RSPO3 and absence of exogenous Wnt, which is suppressed by IWP-2 ( Fig. 3 
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Extended Data Fig. 8a-e ). In the presence of IWP-2, scFv-DKK1c and scFv-DKK1c-RSPO2 were superior or comparable to WNT3A conditioned media in promoting the continuous growth of organoids derived from the pancreas, colon and stomach (corpus); however, they were less active in supporting the growth of liver organoids ( Fig. 3 and Extended Data Fig. 8a -e). The differential activity might be attributed to differential FZD specificity and unknown factors in the conditioned media.
Intestinal organoids represent a model for personalized cystic fibrosis drug screening 21 . While intestinal organoids from healthy donors swell upon the opening of cystic fibrosis transmembrane conductance regulator (CFTR) channels by cAMP, cystic fibrosis organoids will only swell when pretreated with CFTR-activating or -stabilizing drugs. Wnt surrogates supported the growth of strongly budded organoids, in a comparable manner to WNT3A (Extended Data Fig. 8f ), yet they offer the opportunity to culture organoids in defined media, circumventing the interference of unknown components with the assay.
To assess the activities of Wnt surrogates in vivo, we used a recombinant adenoviral expression system to deliver scFv-DKK1c and scFv-DKK1c-RSPO2 systemically in mice. When injected intravenously, adenoviruses infect hepatocytes, resulting in durable expression of the transgenes 22 . In the liver, Wnt proteins are expressed around the central vein 23 , and activate a Wnt-driven pericentral gene expression program, such as glutamine synthetase (encoded by Glul in mice, also known as Glns), in hepatocytes immediately adjacent to the source, resulting in metabolic zonation 24 . We infected wild-type C67Bl/6J mice with adenoviruses expressing scFv-DKK1c (Ad-scFv-DKK1c), scFv-DKK1c-RSPO2 (Ad-scFv-DKK1c-RSPO2), mouse WNT3A (Ad-Wnt3a), human RSPO2-Fc fusion (Ad-RSPO2-Fc) or mouse IgG2α Fc fragment (Ad-Fc) as a negative control (n = 4 mice per group). Infection of the liver was confirmed by quantitative reverse transcription PCR (qRT-PCR), and circulating levels of scFv-DKK1c and scFv-DKK1c-RSPO2 proteins (Extended Data Fig. 9a-f ), but not WNT3A (data not shown), were detected in the peripheral blood. After 7 days, Ad-scFv-DKK1c, Ad-RSPO2-Fc and Ad-Wnt3a modestly expanded the glutamine synthetase-expressing region, while repressing the periportal marker Cyp2f2 (inhibited by Wnt pathway activation) and inducing Axin2 mRNA compared to control mice (Fig. 4a, b and Extended Data Fig. 9g -i). Notably, Ad-scFv-DKK1c plus Ad-RSPO2-Fc, Ad-scFv-DKK1c-RSPO2, and to a lesser extent Ad-Wnt3a plus Ad-RSPO2-Fc elicited a synergistic induction of glutamine synthatase protein (in approximately 90% of the liver lobule) and Axin2 mRNA expression, and suppression of Cyp2f2 mRNA (Fig. 4a, b and Extended Data Fig. 9g -i).
To examine the effect of scFv-DKK1c or scFv-DKK1c-RSPO2 on hepatocyte proliferation, we infected adult C57Bl/6J donor mice with Ad-scFv-DKK1c, Ad-scFv-DKK1c-RSPO2 or Ad-Fc followed by parabiosis in which the circulatory systems of two mice are conjoined (Extended Data Fig. 10a ). Although scFv-Dkk1c and scFv-DKK1c-Rspo2 mRNA were only detected in the livers of donor mice, serum scFv-DKK1c and scFv-DKK1c-RSPO2 proteins, enhanced liver expression of Glul and Axin2, and reduced liver expression of Cyp2f2 were present in donor and recipient mice (Extended Data Fig. 10b -i), confirming that adenoviral infection was confined to the donor. The livers in recipient mice treated with scFv-DKK1c or scFv-DKK1c-RSPO2 exhibited mild hepatomegaly and markedly increased proliferation of HNF4α -positive hepatocytes in all hepatocyte zones, which was most pronounced in the periportal region, similar to recent observations with R-spondin 25 (Fig. 4c, d and Extended Data Fig. 10j ). Therefore, these surrogates activate Wnt signalling in vivo, and alter Wnt-driven hepatic metabolic zonation and proliferation. Given the tight feedback regulation of the Wnt pathway, indirect effects cannot be entirely ruled out. Furthermore, an accompanying study 26 demonstrates that the Wnt surrogates induce proliferation of intestinal crypt cells, confirming their activity on tissues distant from the site of protein production.
The development of surrogate Wnt agonists offers both conceptual insight into Wnt signalling and a practical advance for experimental and therapeutic applications. The ability of the bi-specific heterodimerizer scFv-DKK1c, which concurrently blocks endogenous Wnt binding, to mimic Wnt activity demonstrates that the FZD and LRP5/LRP6 receptors follows the paradigm of signalling activation through receptor dimerization, as seen for growth factor and cytokine receptors 27, 28 . The relative orientations and proximities of the receptors induced by Wnt ligands, and the surrogates, are probably the principle parameters determining the efficiency of signal initiation. However, we cannot rule out the possibility that natural Wnt ligands, and also the cysteineknot growth factor norrin that also activates canonical Wnt signalling by FZD4 and LRP5/LRP6 oligomerization [29] [30] [31] , may possess intrinsic structural features that initiate additional or alternative signalling outcomes, such as by inducing ligand-specific conformational changes in FZD and/or LRP5/6. Future experiments investigating the signalling and functional properties of Wnt proteins versus the surrogates will clarify such questions. The ease of Wnt surrogate production, and the ability of Wnt proteins to target specific FZD subtypes, may allow for a better control of Wnt and FZD pleiotropy, facilitating the introduction of Wnt agonism into the clinic for regenerative medicine applications.
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Cell lines. HEK293 cells stably transfected with the STF plasmid encoding the firefly luciferase reporter under the control of a minimal promoter, and a concatemer of 7 LEF/TCF binding sites 32 , were obtained from J. Nathans. Mouse L cells stably transfected with the STF plasmid and a constitutively expressed Renilla luciferase (control reporter) were obtained from C. Kuo. L cells transfected with a mouse WNT3A expression vector to produce conditioned media were obtained from the ATCC. A375, SH-SY5Y and A549 cells were stably transfected with the BAR plasmid encoding the firefly luciferase reporter under the control of a minimal prompter and a concatemer of 12 TCF/LEF binding sites and a constitutively expressed Renilla luciferase (control reporter) using a lentiviral-based approach 33 . All reporter cell lines were cultured in complete DMEM medium (Gibco) supplemented with 10% FBS, 1% penicillin, streptomycin, and l-glutamine (Gibco), at 37 °C and 5% CO 2 and cultured in the presence of antibiotics for selection of the transfected reporter plasmid. C3H10T1/2 cells were obtained from the ATCC. Human primary MSCs were obtained from Cell Applications, Inc. Mouse primary MSCs were obtained from Invitrogen. Cell lines have not been tested for mycoplasma contamination. Protein constructs, expression and purification. The coding sequence of B12 containing a C-terminal 6× His-tag was cloned into the pET28 vector (Novagen) for bacterial cytoplasmic protein expression. Protein expression was performed in transformed BL21 cells, expression was induced with 0.7 mM IPTG at an OD 600 nm of 0.8 for 3-4 h. Cells were pelleted, lysed by sonication in lysis buffer (20 mM HEPES, pH 7.2, 300 mM NaCl, 20 mM imidazole), and soluble fraction was applied to Ni-NTA agarose (QIAGEN). After washing the resin with lysis buffer containing 500 mM NaCl, B12 was eluted with 300 mM imidazole, and subsequently purified on a Superdex 75 size-exclusion column (GE Healthcare) equilibrated in HBS (10 mM HEPES, pH 7.2, 150 nM NaCl).
XWnt8 was purified from a stably transfected Drosophila S2 cell line coexpressing XWnt8 and mouse FZD8 CRD-Fc described previously 4 . Cells were cultured in complete Schneider's medium (Thermo Fisher Scientific), containing 10% FBS and supplemented with 1% l-glutamine, penicillin and streptomycin (Gibco), and expanded in Insect-Xpress medium (Lonza). A complex of XWnt8 and FZD8 CRD-Fc was captured from the conditioned media on Protein A agarose beads (Sigma). After washing with 10 column volumes of HBS, XWnt8 was eluted with HBS containing 0.1% n-dodecyl-β -d-maltoside (DDM) and 500 mM NaCl, while the FZD8 CRD-Fc remained bound to the beads.
All other proteins were expressed in High Five (Trichoplusia ni) cells (Invitrogen) using the baculovirus expression system. To produce the B12-based surrogate, the coding sequences of B12, a flexible linker peptide comprising of 0, 1, 2 or 3 GSGSG-linker repeats, followed by the C-terminal domain of human DKK1 (residues 177-266), and a C-terminal 6× His-tag, were cloned into the pAcGP67A vector (BD Biosciences). To clone the scFv-based surrogate ligand, the sequence of the Vantictumab was retrieved from the published patent, reformatted into a scFv, and cloned at the N terminus of the surrogate variant containing the GSGSG linker peptide. To produce recombinant FZD CRD for crystallization, surface plasmon resonance measurements, SEC-MALS experiments and functional assays, the CRDs of human FZD1 (residues 113-182), human FZD4 (residues 42-161), human FZD5 (residues 30-150), human FZD7 (residues 36-163), human FZD8 (residues 32-151) and human FZD10 (residues 30-150), containing a C-terminal 3C protease cleavage site (LEVLFQ/GP), a biotin acceptor peptide (BAP)-tag (GLNDIFEAQKIEWHE) and a 6× His-tag were cloned into the same vector. The human FZD8 CRD used for crystallization contained only a C-terminal 6× Histag, in addition to a Asn49Gln mutation to mutate the N-linked glycosylation site. FZD1/FZD8 CRD for inhibition assay contained a C-terminal 3C protease cleavage site, Fc-tag (constant region of human IgG), and a 6× His-tag. Human DKK1 (residues 32-266) with a C-terminal BAP-tag and 6× His-tag, and the two furin-like repeats of human RSPO2 (residues 36-143) with a N-terminal Fc-tag and a C-terminal 6× His-tag, were cloned also into the pAcGP67A vector. All proteins were secreted from High Five insect cells grown in Insect-Xpress medium, and purified using Ni-NTA affinity purification, and size-exclusion chromatography equilibrated in HBS (10 mM HEPES, pH 7.3, 150 nM NaCl). Enzymatic biotinylation was performed in 50 mM bicine, pH 8.3, 10 mM ATP, 10 mM magnesium acetate, 0.5 mM d-biotin with recombinant glutathione S-transferase (GST)-tagged BirA ligase overnight at 4 °C, and proteins were subsequently re-purified on a Superdex 75 size-exclusion column to remove excess biotin. Computational design of FZD8-specific binding domain. We attempted to mimic the native Wnt-FZD lipid-protein interaction with a de novo designed protein-protein binding interface. A 13-residue alanine helix was docked against the lipid-binding cleft using Foldit 34 . This structural element was grafted onto a diverse set of native helical proteins using the Rosetta Epigraft 35 application to discover scaffolds with compatible, shape-complementary backbones. Prototype designs were selected by interface size and optimized using RosettaScripts 36 to perform side-chain redesign. 50 selected designs were further manually designed to ensure charge complementarity and non-essential mutations were reverted to the wild-type amino acid identity to maximize stability. DNA was obtained from Gen9 and screened for binding via yeast surface display as previously described with 1 μ M biotinylated FZD8 CRD pre-incubated with 025 µM SAPE (Life Technologies) 37 . A design based on the scaffold with PDB code 2QUP, a uncharacterized four-helix bundle protein from Bacillus halodurans, demonstrated binding activity under these conditions, whereas knockout mutants Ala52Arg and Ala53Asd made using the Kunkel method 38 abrogated binding, verifying that the functional interface used the predicted residues. Wild-type scaffold 2QUP did not bind, confirming that activity was specifically due to design. Affinity maturation of B12. To improve the affinity of the original design, a full-coverage site-saturation mutagenesis library was constructed for design based on the 2QUP scaffold via the Kunkel mutagenesis method 38 using forward and reverse primers containing a 'NNK' degenerate codon and 21-bp flanking regions (IDT). A yeast library was transformed as previously described 39 and sorted for three rounds, collecting the top 1% of binders using the BD Influx cell sorter. Naive and selected libraries were prepared and sequenced, and the data was processed as previously described 37 using a Miseq (Illumina) according to manufacturer protocols. The most enriched 11 mutations were identified by comparison of the selected and unselected pools of binders and were combined in a degenerate library containing all enriched and wild-type amino acid identities at each of these positions. This combination library was assembled from the oligonucleotides (IDT) listed below for a final theoretical diversity of around 800 k distinct variants. This library was amplified, transformed, and selected to convergence over five rounds, yielding the optimized variant B12.
Ultramer1_fwd_164bp 5 ′ -G CT AG TG GT GG AG GA GG CT CT GG TG GA GG C G GT AG CG GA GG CG GA GG GT CG GC TA GC CA TA TG GG CG TG AG CT TT AG CG AA GT GA TG GG CA AA CA GA AA GA TG AA CA GG CG CGTGAACAGCTGAA AGAAGGCATGAWAAAAATTGAAGAACAGGGCAAAAAGCT-3′ ; U lt ra me-r2 _r ev _133bp 5 ′ -A GC CA CG AC GT TC TT CC AG AT TC KK TC CC AG AA AA CC C G CC KS CR MCGCAAAARBCGCCACCGCTGCGR CA TA TT TC TG CA GC TC T T CC TG GG TA CG GG TT TC GC TC AG CT TT TTGCCCTGTTCTTCAATTTT-3′ ; Ultramer3_fwd_147bp 5 ′ -A AT CT GG AA GA AC GT CG TG GC TT TA AT CG TC GG GG CA AA GA AG AA AT TG GCAAAATTAGCGGAGAAGTGTACMWAAAACT GTTAGACCTGAAAAAAGCGGTGCGTGCGAAAGAAAAAAAGGGACTGGA TATTCTGAATATGGTGGGC-3′ ; Ultramer4_rev_128bp 5 ′ -GTTGTTATCAGA TCTCTATTACAAGTCCTCTTCAGAAATAAGCTTTTGTTCGGATCCGCCC CCCTCGAGCGCAKRAMYACKCTCCAGGRKGCCCTTAATCTCGCCCACC ATATTCAGAATATCCAGTC-3′ . Complex crystallization and structure determination. The B12-FZD8 CRD(N49Q) complex was formed by mixing purified B12 and FZD8 CRD(N49Q) in stoichiometric quantities. The complex was then treated with 1:100 (w/w) carboxypeptidase A (Sigma) overnight at 4 °C, and purified on a Superdex 75 (GE Healthcare Life Sciences) size-exclusion column equilibrated in HBS. Purified complex was concentrated to around 15 mg ml −1 for crystallization trials. Crystals were grown by hanging-drop vapour diffusion at 295 K, by mixing equal volumes of the complex and reservoir solution containing 42-49% PEG 400, 0.1 M Tris, pH 7.8-8.2, 0.2 M NaCl, or 20% PEG 3000, 0.1 M sodium citrate, pH 5.5. While the PEG 400 condition is already a cryo-protectant, the crystals grown in the PEG 3000 condition were cryoprotected in reservoir solution supplemented with 20% glycerol before flash freezing in liquid nitrogen. Crystals grew in space groups P2 1 (PEG 400 condition) and P2 (PEG 3000 condition), respectively, with 2 and 4 complexes in the asymmetric units. Cell dimensions are listed in Supplementary  Table 1 . Data were collected at beamline 8.2.2 at the Advanced Light Source (ALS), Lawrence Berkeley National Laboratory. All data were indexed, integrated, and scaled with the XDS package 40 . The crystal structures in both space groups were solved by molecular replacement with the program PHASER 41 using the structure of the FZD8 CRD (PDB code 1IJY) and the designed model of a minimal core of B12 as search models. Missing residues were manually build in COOT 42 after initial rounds of refinement. Several residues at the N terminus (residues 1 to 16/17/20/21), at the C terminus (residues after 117) and several residues within loop regions were unstructured and could not been modelled. Furthermore, we observed that in both crystal forms, B12 underwent domain swapping, and one B12 molecule lent helix 3 and 2 to another B12, resulting in a closely packed B12 homodimer. The density of the loops connecting helixes 1 and 2, and 3 and 4 were clearly visible, and folded into helical turns. Yet, SEC-MALS experiments confirmed that B12 existed as a monomer in solution, and complexed FZD8 CRD with a 1:1 stoichiometry. PHENIX Refine 43 was used to perform group coordinate refinement (rigid body refinement), followed by individual coordinate refinement using gradient-driven minimization applying stereo-chemical restraints, NCS restraints, and optimization of X-ray/stereochemistry weight, and individual B-factor refinement. Initial rounds of refinement were aided by restraints from the high-resolution mouse FZD8 CRD structure as a reference model. Real space refinement was performed in COOT into a likelihood-weighted SigmaA-weighted 2mF o − DF c map calculated in PHENIX. The final model in the P2 space group was refined to 3.20 Å with R work and R free values of 0.2002 and 0.2476, respectively (Supplementary Table 1 ). The quality of the structure was validated with MolProbity 44 . 99.5% of residues are in the favoured region of the Ramachandran plot, and no residue in the disallowed region. The structure within the P2 1 space group was refined to 2.99 Å with R work and R free values of 0.2253 and 0.2499, respectively, with 99.2% of residues in the favoured region of the Ramachandran plot, and no residues in the disallowed region. See Supplementary Table 1 for data and refinement statistics. Structure figures were prepared with the program PYMOL. Affinity measurements of B12 and scFv-DKK1c interaction with FZD CRDs. Binding measurements were performed by surface plasmon resonance on a BIAcore T100 (GE Healthcare) and all proteins were purified on SEC before experiments. Biotinylated FZD1 CRD, FZD5 CRD, FZD7 CRD and FZD8 CRD were coupled at a low density to streptavidin on a SA sensor chip (GE Healthcare). An unrelated biotinylated protein was captured at equivalent coupling density to the control flow cells. Increasing concentrations of B12 and scFv-DKK1c were flown over the chip in HBS-P (GE Healthcare) containing 10% glycerol and 0.05% BSA at 40 μ l ml −1 . The chip surface was regenerated after each injection with 2 M MgCl 2 in HBS-P or 50% ethylene glycol in HBS-P (scFv-DKK1c measurements), or 4 M MgCl 2 in HBS-P (B12 measurements) for 60 s. Curves were referencesubtracted and all data were analysed using the Biacore T100 evaluation software version 2.0 with a 1:1 Langmuir binding model to determine the K d values. Analysis of yeast displayed B12 binding to human FZD CRDs. To characterize the FZD-specificity of B12, the yeast display vector encoding B12 was transformed into EBY100 yeast. To induce the display of B12 on the yeast surface, cells were growing in SGCAA medium 45, 46 for 2 days at 20 °C. 1 × 10 6 yeast cells per condition were washed with PBE (PBS, 0.5% BSA, 2 mM EDTA), and stained separately with 0.06-1,000 nM biotinylated FZD1/4/5/7/8/10 CRDs for 2 h at 4 °C. After washing twice with ice-cold PBE, bound FZD CRDs were labelled with 10 nM strepdavidin-Alexa647 for 20 min. Cells were fixed with 4% paraformaldehyde, and bound FZD CRD was analysing on an Accuri C6 flow cytometer. Plasmids, cell culture and cell labelling for single-molecule fluorescence microscopy. FZD8 fused to an N-terminal HaloTag 47 and LRP6 fused to an N-terminal SNAP-tag 48 were cloned into the pSEMS-26m vector (Covalys Biosciences) by cassette cloning 49, 50 . The template pSEMS-26m vectors had been coded with DNA sequences of the SNAP-tag or the HaloTag, respectively, together with an Igκ leader sequence (from the pDisplay vector, Invitrogen) as described previously 50 . The genes of full-length mouse Fzd8 or human LRP6 without the N-terminal signal sequences were inserted into pSEMS-26m via the XhoI and AscI or AscI and NotI, restriction sites, respectively. A plasmid encoding a model transmembrane protein, maltose-binding protein fused to a transmembrane domain, fused to an N-terminal HaloTag was prepared as described recently 13 . HeLa cells were cultivated at 37 °C, 5% CO 2 in MEM Earle's (Biochrom AG, FG0325) supplemented with 10% fetal calf serum and 1% nonessential amino acids. Cells were plated in 60-mm cell culture dishes to a density of 50% confluence and transfected via calcium phosphate precipitation 49 . 8-10 h after transfection, cells were washed twice with PBS and the medium was exchanged, supplied with 2 μ M porcupine inhibitor IWP-2 for inhibiting maturation of endogenous Wnt in HeLa cells 51 . 24 h after transfection, cells were plated on glass coverslips pre-coated with PLL-PEG-RGD 52 for reducing nonspecific binding of dyes during fluorescence labelling. After culturing for 12 h, coverslips were mounted into microscopy chambers for live-cell imaging. SNAP-tag and HaloTag were labelled by incubating cells with 50 nM benzylguanine-DY649 (SNAP-Surface 649, New England Biolabs) and 80 nM of HaloTag tetramethylrhodamine ligand (HTL-TMR, Promega) for 20 min at 37 °C. Under these conditions, effective degrees of labelling estimated from single molecule assays with a HaloTag-SNAP-tag fusion protein were ~ 40% for the SNAP-tag and ~ 25% for the HaloTag 13 . After washing three times with PBS, the chamber was refilled with MEM containing 2 μ M IWP-2 for single-molecule fluorescence imaging. Single-molecule fluorescence microscopy. Single-molecule fluorescence imaging was carried out by using an inverted microscope (Olympus IX71) equipped with a triple-line total internal reflection (TIR) illumination condenser (Olympus) and a back-illuminated EMCCD camera (iXon DU897D, 512 × 512 pixel from Andor Technology). A 561-nm diode solid state laser (CL-561-200, CrystaLaser) and a 642-nm laser diode (Luxx 642-140, Omicron) were coupled into the microscope for excitation. Laser lights were reflected by a quad-line dichroic beam splitter (Di R405/488/561/647, Semrock) and passed through a TIRF objective (UAPO 150× /1.45, Olympus). For simultaneous dual-colour detection, a DualView microimager (Optical Insight) equipped with a 640 DCXR dichroic beamsplitter (Chroma) in combination with bandpass filters FF01-585/40 and FF01 670/30 (Semrock), respectively, was mounted in front of the camera. The overlay of the two channels was calibrated by imaging fluorescent microbeads (TetraSpeck microspheres 0.1 μ m, T7279, Invitrogen), which were used for calculating a transformation matrix. After channel alignment, the deviation between the channels was below 10 nm.
For single-molecule imaging, typical excitation powers of 1 mW at 561 nm and 0.7 mW at 642 nm measured at the objective were used. Time series of 150-300 frames were recorded at 30 Hz (4.8-9.6 s). An oxygen scavenging system containing 0.5 mg ml −1 glucose oxidase, 40 mg ml −1 catalase, and 5% (w/v) glucose, together with 1 μ M ascorbic acid and 1 μ M methyl viologene, was added to minimize photobleaching 53 . Receptor dimerization was initiated by incubating with 100 nM Wnt proteins or surrogates. Images were acquired after 5 min incubation in the presence of the ligands. All live-cell imaging experiments were carried out at room temperature. Receptor heterodimerization analysis. A 2D Gaussian mask was used for localizing single emitters 54, 55 . For colocalization analysis to determine the heterodimerization fraction, particle coordinates from two channels were aligned by a projective transformation (cp2tform of type 'projective' , MATLAB 2012a) according to the transformation matrix obtained from microbead calibration measurement. Particles colocalized within a distance of 150 nm were selected. Only co-localized particles, which could be tracked for at least 10 consecutive frames (that is, molecules co-locomoting for at least 0.32 s) were accepted as receptor heterodimers or hetero-oligomers, which has been previously found to be a robust criterion for protein dimerization 13 . The fraction of heterodimerization or hetero-oligomerization was determined as the number of co-locomotion trajectories with respect to the number of the receptor trajectories. Since the receptor expression level of FZD8 or LRP6 was variable in the transiently transfected cells, only cells with similar receptor expression levels were considered (less than three times the excess of one subunit over the other). The smaller number of trajectories of either FZD8 or LRP6 was regarded as the limiting factor and therefore taken as a reference for calculating the heterodimerized/heterooligomerized fraction. Oligomerization values were not corrected for the degree of labelling. Single-molecule tracking. Single-molecule trajectories were reconstructed using the multi-target tracing (MTT) algorithm 56 . The detected trajectories were evaluated with respect to their step length distribution to determine the diffusion coefficients. For a reliable quantification of local mobilities, we estimated diffusion constants from the displacements with three frames (96 ms).
Step-length histograms were obtained from all single molecule trajectories and fitted by a twocomponent model of Brownian diffusion, thus taking into account the intrinsic heterogeneity of protein diffusion in the plasma membrane 57, 58 . A bimodal probability density function p(r) was used for a nonlinear least square fit of the step-length histogram:
where α i is the percentage of the fraction, σ δ = D n t 2 i i 2 contains the diffusion coefficient of each fraction (nδt = 96 ms). Average diffusion coefficients were determined by weighting the diffusion coefficients with the corresponding fractions. Single-molecule intensity assay. Single-molecule intensity distribution of individual diffraction-limited spots was extracted from the first 50 images of the recorded time lapse image sequence, in which photobleaching of dyes was kept below 10% 13 . Oligomerization of receptors was evaluated by fitting the obtained single molecule intensity with a multi-component Gaussian distribution function 59 . To ensure a reliable analysis, monomeric receptors were first distinguished based on the observation that monomers diffused much faster than oligomers. Therefore, the characteristic intensity distribution of monomeric receptor subunits was obtained by tracking of the fast mobile fraction. Fractions of the monomer, dimer, trimer and higher oligomers were then de-convoluted from the single molecule intensity distribution, presuming that intensities of clusters were multiples of the monomer intensity distribution. STF and BAR luciferase reporter assays. Immortal cells were seeded in triplicate for each condition in 96-well plates, and stimulated with surrogates, XWnt8, WNT3A conditioned media, control proteins, or other treatments for 20-24 h. After washing cells with PBS, cells in each well were lysed in 30 μ l passive lysis buffer (Promega). 10 μ l per well of lysate was assayed using the Dual Luciferase Assay kit (Promega) and normalized to the Renilla luciferase signal driven constitutively by the human elongation factor-1 alpha promoter to account for cell a patient at Wilhelmina Children's Hospital WKZ-UMCU. Informed consent for the generation and use of these organoids for experimentation was approved by the ethical committee at University Medical Center Utrecht (UMCU) (TcBio 14-008). Human stomach organoids, derived from normal corpus and pylorus, were from patients that underwent partial or total gastrectomy at the University Medical Centre Utrecht (UMCU) and were established as described 19, 64, 65 . Pancreas organoids were obtained from the healthy part of the pancreas of patients undergoing surgical resection of a tumour at the University Medical Centre Utrecht Hospital (UMC) and were established as described 66, 67 . The liver organoids were derived from freshly isolated normal liver tissue from a patient with metastatic CRC who presented at the UMC hospital (ethical approval code TCBio 14-007) and were established as described 20, 68 .
For the performance of 3D cultures, Matrigel (BD Biosciences) was used and overlaid with a liquid medium consisting of DMEM/F12 advanced medium (Invitrogen), supplemented with additional factors as outlined below. 2% RSPO3-CM (produced via the r-PEX protein expression platform at U-Protein Express BV), WNT3A conditioned medium (50%, produced using stably transfected L cells in the presence of DMEM/F12 advanced medium supplemented with 10% FBS), and Wnt and Wnt/RSPO2 surrogates at different concentrations were added as indicated. Single-cell suspensions of normal human organoids were cultured in duplicate or triplicate in round-bottom 96-well plates to perform a cell viability test using Cell Titer-Glo 3D (Promega). In brief, organoids were trypsinized to single-cell suspension and plated in 100 μ l medium in the presence of the different reagents. 3 μ M IWP-2 was added to inhibit endogenous Wnt lipidation and secretion. After 12 days, 100 μ l of Cell Titer-Glo 3D was added, plates were shaken for 5 min, incubated for an additional 25 min and centrifuged before luminescence measurement. In vivo experiments. All animal experiments were conducted in accordance with procedures approved by the IACUC at Stanford University. Experiments were not randomized, the investigators were not blinded, and all samples/data were included in the analysis. Group sample sizes were chosen based on (1) previous experiments, (2) performance of statistics analysis, and (3) logistical reasons with respect to full study size, to accommodate all groups. Adenoviruses (E1 and E3 deleted, replication deficient) were constructed to express scFv-DKK1c or scFv-DKK1c-RSPO2 with an N-terminal signal peptide and C-terminal 6× His-tag (Ad-scFv-DKK1c or Ad-scFv-DKK1c-RSPO2), respectively. Adenoviruses expressing mouse IgG2α Fc (Ad-Fc), human RSPO2-Fc fusion protein (Ad-RSPO2-Fc) and mouse WNT3A (Ad-Wnt3a) were constructed and described in the companion paper by Yan et al. 26 The adenoviruses were cloned, purified by CsCl gradient, and titred as previously described 69 . Adult C57Bl/6J mice were purchased from Taconic Biosciences. Adult C57Bl/6J mice between 8-10 weeks old were injected intravenously with a single dose of adenovirus at between 1.2 × 10 7 p.f.u. to 6 × 10 8 p.f.u. per mouse in 0.1 ml PBS. Serum expression of Ad-scFv-DKK1c or Ad-scFv-DKK1c-RSPO2 were confirmed by immunoblotting using mouse anti-6× His (Abcam ab18184, 1:2,000) or rabbit anti-6× His (Abcam ab9108, 1:1,000), respectively. All experiments used n = 4 mice per group and repeated at least twice.
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Extended Data Figure 1 | De novo design and engineering of B12 . a, Design strategy of a FZD8 CRD-specific binding domain. b, Designed binding of B12 (orange) to the FZD8 CRD (blue), with XWnt8 and Wnt lipid (purple) modelled onto the structure to highlight competitive binding modes. Residues outside of the 'lipid groove helix' were designed to make FZD8-specific contacts to promote specificity. c, Comparison between the designed (left) and observed (right) conformation. d, Affinity maturation of parental B12 by yeast cell surface display identified enriched point mutations that were assembled in a degenerate library and selected to yield the final, optimized B12.
Extended Data Figure 5 | Single-molecule intensity analysis of LRP6 and FZD8 under different conditions. Single-molecule intensity analysis for quantifying LRP6 (a-f) and FZD8 (g-l) oligomerization in representative cells under different conditions. Raw images after treatment with scFv-DKK1c (b, h), B12-DKK1c (c, i), XWnt8 (d, j), WNT3A (e, k) and without treatment (a, g). On the basis of their intensities, individual diffraction-limited spots in the raw images were classified as monomers (blue circle), dimers (green circle), trimers (yellow circle) and higher oligomers (red circle), respectively. f, l, m, Different oligomer fractions summarized as the ratio of the classified species number to the total number of detected diffraction-limited spots. More than 7,200 single complex intensities were examined for each condition.
